{"id":2313,"date":"2024-04-10T11:01:39","date_gmt":"2024-04-10T08:01:39","guid":{"rendered":"https:\/\/www.sightsciences.com\/us\/?p=2313"},"modified":"2024-05-28T13:03:41","modified_gmt":"2024-05-28T10:03:41","slug":"sight-sciences-announces-the-publication-of-large-scale-real-world-migs","status":"publish","type":"post","link":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/","title":{"rendered":"Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma"},"content":{"rendered":"<div class=\"ndq-section\">\n<div id=\"ndq-content\" class=\"row ndq-8831\">\n<div class=\"column large-12\">\n<div class=\"region region-content\">\n<div class=\"hidden\" data-drupal-messages-fallback=\"\"><\/div>\n<div id=\"block-nir-pid4158-content\" class=\"block--system-main-block block--system-main-block--8831 block--content--system-main-block block--content--system-main-block--8831 block--d3e5cab3-701e-469f-8150-a0c2ef34d4c7 block--d3e5cab3-701e-469f-8150-a0c2ef34d4c7--8831 block block-system block-system-main-block\">\n<article class=\"node node--nir-news--full node--type-nir-news node--view-mode-full node--promoted\">\n<div class=\"file-link pdf-file-link\"><span class=\"file file--mime-application-pdf file--application-pdf\"><a href=\"\/wp-content\/uploads\/sites\/4\/2024\/04\/IRIS-Registry-2-Year-Press-Release.pdf\" target=\"_blank\" rel=\"noopener\" type=\"application\/pdf\">PDF Version<\/a><\/span><\/div>\n<div class=\"node__content\">\n<div class=\"box__wrap\"><\/div>\n<p>&nbsp;<\/p>\n<h3 class=\"subhead-gnw\">The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes<\/h3>\n<p>MENLO PARK, Calif., April 10, 2024 (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sX40sgLtO5UJQxgEXdEU9py8RDhgh2kgMzUDupAhwqTa5pan_Jns_LOWbHmoAYRgV_Xd0neS7MB--NraMb2KEA4py8GbxTJwTwmKhOgc3N4=\" target=\"_blank\" rel=\"nofollow noopener\">Sight Sciences<\/a>, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients\u2019 lives, today announced the results as published in the American Journal of Ophthalmology (\u201cAJO\u201d) International of the large scale, comparative real-world clinical outcomes study of patients treated by three leading, minimally invasive glaucoma surgery (\u201cMIGS\u201d) technologies.<\/p>\n<p>Using the American Academy of Ophthalmology <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3ZfapO1ZMbBPMpvkV1mnDPlVMIBKx0CB4SndF8_HaCamE2DvIH9Lfx0g-xN2TSlU9RIEABWeqzg4uH-3B3AWhA==\" target=\"_blank\" rel=\"nofollow noopener\">IRIS<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NV5eTghC7eZ5T93Welbtze8W_Icolp4GTpxLsvS6qAs00mYweqDdVyAKPsxtxnMB-fn1G19LYpeoHztNDoq2Cg==\" target=\"_blank\" rel=\"nofollow noopener\"><sup>\u00ae<\/sup><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n0Kdh8MY1hZk8SM7kqhoPIf_4CLSa4BXyzocIjjIjmDlpjByOHe58YyJO9kHyhPH1Rx-BNKwg55vnofiJyvpU8ModfAyLX1PkF_szv4aZdQ=\" target=\"_blank\" rel=\"nofollow noopener\"> Registry<\/a> (Intelligent Research in Sight), the largest specialty society clinical data registry in all of medicine and the first comprehensive eye disease clinical registry in the United States, this large-scale MIGS study evaluated long-term 2-year post-surgical outcomes among patients with primary open-angle glaucoma (\u201cPOAG\u201d) treated with the three most commonly used FDA-approved\/cleared <em>ab interno <\/em>MIGS devices in the U.S. (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Mbf9x0tdHCvZa_qYuBJuitBUuhevQAggmWC3vzfSQDhMdn6EuMK7xbO3jjzBdZrP3pPHCHmsDSYuFsnx6HTp6HzA-kAjWTgoq3oL5I2iuhA=\" target=\"_blank\" rel=\"nofollow noopener\">OMNI Surgical System<\/a> (\u201cOMNI\u201d), Hydrus<sup>\u00ae<\/sup> Microstent, and iStent inject<sup>\u00ae<\/sup>) combined with cataract surgery, as well as for cataract surgery alone.<\/p>\n<p>OMNI facilitates a unique implant-free, <em>ab interno<\/em> procedure that comprehensively addresses the three primary areas of resistance in the conventional outflow pathway. OMNI technology has been cleared by the FDA for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma.<\/p>\n<p><strong>Baseline Patient Characteristics: <\/strong><\/p>\n<ul>\n<li>The entire study cohort consisted of 77,391 patients with glaucoma and 109,745 glaucomatous eyes<\/li>\n<li>6,632 patients and 9,000 eyes received a MIGS procedure in combination with cataract surgery, and the remainder received cataract surgery alone<\/li>\n<li>The four cohorts had generally similar baseline characteristics in terms of intraocular pressure (\u201cIOP\u201d) and mean number of IOP-lowering medications (see table below)<\/li>\n<li>The overall population was divided into two subgroups depending on the baseline, pre-surgical lOP; &gt; 18 mmHg and \u2264 18 mmHg. The primary treatment goal for the high baseline IOP group (&gt; 18mmHg) was IOP reduction, with a secondary goal to reduce medication burden. The primary treatment goal for the low baseline IOP group (<u>&lt;<\/u> 18mmHg) was to reduce medication burden.<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse; width: 100%; border: solid black 1pt;\" role=\"presentation\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: solid black 1pt;\"><strong>Baseline<\/strong><\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\" colspan=\"2\"><strong>Group 1 Pre-op<\/strong><br \/>\n<strong>(&gt; 18mmHg IOP)<\/strong><\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\" colspan=\"2\"><strong>Group 2 Pre-op<\/strong><br \/>\n<strong>(\u2264 18mmHg IOP)<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"max-width: 40%; width: 40%; min-width: 40%; ;border-top: solid black 1pt; border-right: solid black 1pt; border-bottom: solid black 1pt; border-left: solid black 1pt; vertical-align: top;\"><\/td>\n<td style=\"max-width: 15%; width: 15%; min-width: 15%; ;border-top: solid black 1pt; border-right: solid black 1pt; border-bottom: solid black 1pt; border-left: solid black 1pt; text-align: center; vertical-align: top;\"><strong>Mean IOP<br \/>\n(mmHg)<\/strong><\/td>\n<td style=\"max-width: 15%; width: 15%; min-width: 15%; ;border-top: solid black 1pt; border-right: solid black 1pt; border-bottom: solid black 1pt; border-left: solid black 1pt; text-align: center; vertical-align: top;\"><strong>Number of<br \/>\nIOP-Lowering<br \/>\nMedication<br \/>\nClasses<\/strong><\/td>\n<td style=\"max-width: 15%; width: 15%; min-width: 15%; ;border-top: solid black 1pt; border-right: solid black 1pt; border-bottom: solid black 1pt; border-left: solid black 1pt; text-align: center; vertical-align: top;\"><strong>Mean<br \/>\nIOP<br \/>\n(mmHg)<\/strong><\/td>\n<td style=\"max-width: 15%; width: 15%; min-width: 15%; ;border-top: solid black 1pt; border-right: solid black 1pt; border-bottom: solid black 1pt; border-left: solid black 1pt; text-align: center; vertical-align: top;\"><strong>Number of<br \/>\nIOP-Lowering<br \/>\nMedication Classes<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top; border: solid black 1pt;\">OMNI Surgical System<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">22.5<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">1.95<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">14.1<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">2.01<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top; border: solid black 1pt;\">Hydrus Microstent<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">22.5<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">1.89<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">14.2<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">1.89<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top; border: solid black 1pt;\">iStent inject<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">22.2<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">1.58<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">14.4<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">1.58<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top; border: solid black 1pt;\">Cataract-Surgery Alone<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">22.8<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">1.60<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">14.5<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">1.62<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Clinical Outcomes: <\/strong><\/p>\n<ul>\n<li style=\"text-align: justify;\">At 24 months, high baseline IOP (&gt;18 mmHg) patients who received the outflow procedure using OMNI technology had:\n<ul>\n<li style=\"text-align: justify;\">The greatest numerical reduction in IOP, and<\/li>\n<li style=\"text-align: justify;\">The greatest numerical reduction in medication use<\/li>\n<\/ul>\n<\/li>\n<li style=\"text-align: justify;\">At 24 months, low baseline IOP (\u226418 mmHg) patients who received the outflow procedure using OMNI technology had:\n<ul>\n<li style=\"text-align: justify;\">The greatest numerical reduction in IOP, and<\/li>\n<li style=\"text-align: justify;\">A statistically significantly greater mean medication use reduction compared to all other treatment groups<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<table style=\"border-collapse: collapse; width: 100%; border: solid black 1pt;\" role=\"presentation\">\n<tbody>\n<tr>\n<td style=\"vertical-align: top; border: solid black 1pt;\"><strong>Post Treatment<\/strong><br \/>\n<strong>@ 24 Months<\/strong><\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\" colspan=\"2\"><strong>Group 1 &gt; 18mmHg IOP<\/strong><br \/>\n<strong>Treatment Goal:<br \/>\nIOP and Medication Reduction<\/strong><\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\" colspan=\"2\"><strong>Group 2 \u2264 18mmHg IOP<\/strong><br \/>\n<strong>Treatment Goal:<br \/>\nMedication Reduction <\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"max-width: 40%; width: 40%; min-width: 40%; ;border-top: solid black 1pt; border-right: solid black 1pt; border-bottom: solid black 1pt; border-left: solid black 1pt; vertical-align: top;\"><\/td>\n<td style=\"max-width: 15%; width: 15%; min-width: 15%; ;border-top: solid black 1pt; border-right: solid black 1pt; border-bottom: solid black 1pt; border-left: solid black 1pt; text-align: center; vertical-align: top;\"><strong>Mean<br \/>\nReduction in<br \/>\nIOP mmHg (%<br \/>\nChange From<br \/>\nBaseline)<\/strong><\/td>\n<td style=\"max-width: 15%; width: 15%; min-width: 15%; ;border-top: solid black 1pt; border-right: solid black 1pt; border-bottom: solid black 1pt; border-left: solid black 1pt; text-align: center; vertical-align: top;\"><strong>Mean<br \/>\nMedication<br \/>\nClass<br \/>\nReduction <\/strong><\/td>\n<td style=\"max-width: 15%; width: 15%; min-width: 15%; ;border-top: solid black 1pt; border-right: solid black 1pt; border-bottom: solid black 1pt; border-left: solid black 1pt; text-align: center; vertical-align: top;\"><strong>Mean<br \/>\nReduction in<br \/>\nIOP mmHg (%<br \/>\nChange From<br \/>\nBaseline)<\/strong><\/td>\n<td style=\"max-width: 15%; width: 15%; min-width: 15%; ;border-top: solid black 1pt; border-right: solid black 1pt; border-bottom: solid black 1pt; border-left: solid black 1pt; text-align: center; vertical-align: top;\"><strong>Mean<br \/>\nMedication<br \/>\nClass<br \/>\nReduction <\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top; border: solid black 1pt;\">OMNI Surgical System<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-6.64 (30%)<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-1.34<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-0.47 (3%)<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-1.42<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top; border: solid black 1pt;\">Hydrus Microstent<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-5.71 (25%)<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-1.20<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">+0.03 (0%)<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-1.18<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top; border: solid black 1pt;\">iStent inject<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-4.96 (22%)<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-0.86<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-0.17 (1%)<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-0.95<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top; border: solid black 1pt;\">Cataract-Surgery Alone<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-5.55 (24%)<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-0.67<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-0.07 (0%)<\/td>\n<td style=\"text-align: center; vertical-align: top; border: solid black 1pt;\">-0.65<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\u201cConsistent with our many prior published studies, this large-scale, real-world MIGS dataset from the IRIS Registry, as analyzed by Verana Health<sup>\u00ae <\/sup>and published in a top peer-reviewed journal, corroborates that the OMNI procedure is efficacious as it delivers clinically meaningful and durable reductions in both intraocular pressure and medication use at two years. OMNI technology was designed with the goal of restoring the natural outflow process of the eye by addressing the three areas of resistance associated with primary open-angle glaucoma. We are excited to see that large-scale comparison studies of MIGS standards-of-care continue to corroborate the robust IOP reduction and medication reduction associated with the comprehensive OMNI outflow procedure,\u201d said Paul Badawi, co-founder and CEO of Sight Sciences. \u201cI\u2019d also like to thank the team at Verana Health and the American Academy of Ophthalmology for making critical, real-world, large-scale, clinical outcome information in the IRIS Registry available for all stakeholders, including eyecare providers, payors, industry, and researchers.\u201d<\/p>\n<p><strong>Authors and affiliations: <\/strong><br \/>\nMichael Mbagwu (Stanford University School of Medicine, Palo Alto, CA), Richard Chapman (Verana Health, San Francisco, CA), Kristian Garcia Aesara, Chapel Hill, NC, Aesara, Chapel Hill, NC 3, Jaime E Dickerson Jr (Sight Sciences, Menlo Park, CA, and North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX), and Louis B Cantor (Indiana University School of Medicine, Department of Ophthalmology, Indianapolis, IN).<\/p>\n<p><strong>Paper Reference: <\/strong><br \/>\nMichael Mbagwu, Richard Chapman, Kristian Garcia, Cristina Masseria, Jaime E Dickerson, Louis B Cantor, Ab Interno Minimally Invasive Glaucoma Surgery Combined with Cataract Surgery and Cataract Surgery Alone: IRIS<sup>\u00ae<\/sup> Registry Study, AJO International, 2024,100015, ISSN 2950-2535.<\/p>\n<p><strong>About Sight Sciences<\/strong><br \/>\nSight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients\u2019 lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world\u2019s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company\u2019s OMNI<sup>\u00ae<\/sup> Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma (\u201cPOAG\u201d); and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm\u2019s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world\u2019s leading cause of irreversible blindness. The Company\u2019s TearCare<sup>\u00ae<\/sup> System technology is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (\u201cMGD\u201d) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company\u2019s SION<sup>\u00ae<\/sup> Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zflOfDycuwYX36rZMpljkKCjtP1C5dwxlG9qIoMqmwvgByax4o3NFI15FdZuFN9RG1wsH2OGDldY7_82D7KZBRtDkM79vQ_0BlyiWQ_Veb0=\" target=\"_blank\" rel=\"nofollow noopener\">sightsciences.com<\/a> for more information.<br \/>\n<strong>About Verana Health<\/strong><br \/>\nVerana Health<sup>\u00ae<\/sup> (\u201cVerana\u201d) is revolutionizing patient care and clinical research by unlocking the potential of real-world data. Verana has an exclusive real-world data network of 90 million de-identified patients from more than 20,000 clinicians, stemming from its exclusive data partnerships with three leading medical societies. Verana harnesses deep expertise, secure advanced technology, and direct access to exclusive, near real-time data sources to deliver actionable quality insights that help companies make sense of the data. Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2q6pMM-9hrJC_9FybK_s1IbbYJnhBdj9VXV_y1dl5ABwRW9OC5gNLot43vWHgDASWsIIhHKj81LgRKmCvPz5m01amk1QJbcf0v9DLeDB1cM=\" target=\"_blank\" rel=\"nofollow noopener\">veranahealth.com<\/a> for more information.<br \/>\nSight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.<\/p>\n<p><br class=\"\" \/>Hydrus is a registered trademark of Alcon Vision LLC.<br \/>\niStent inject is a registered trademark of Glaukos Corporation.<br \/>\nIRIS is a registered trademark of the American Academy of Ophthalmology.<br \/>\nVerana Health is a registered trademark of Verana Health.<br \/>\n\u00a9 2024 Sight Sciences. All rights reserved. 04\/2024 OM-3150-US.v1<\/p>\n<p><strong>Media contact:<\/strong><br \/>\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_IEd0_rBotzvVq-vU2OdH21cVbRyKdxq319Jlkk6sMW4FtFzwcECJC2ZGcd_qItHPR536PKWbd6UxQpbu39yrzOd4NDBjKgtjXIc9ZujwsM=\" target=\"_blank\" rel=\"nofollow noopener\">pr@SightSciences.com<\/a><br \/>\n<strong>Investor contact:<\/strong><br \/>\nPhilip Taylor<br \/>\nGilmartin Group<br \/>\n415.937.5406<br \/>\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d47QRw_M7650qQL5Aito8JhAJn08hCLqjTsFDqoDYq6aMl-_s9NCPQhhT0ASZ_S28oY8OokkBPFRn1T76a5GnWUQrd0U9tWXyPEbSnwRhVLE5gvMzV-2J3jV32i9Tf2Vg_5YoY7PoZS6XimQKHT6jg==\" target=\"_blank\" rel=\"nofollow noopener\">Investor.Relations@SightSciences.com<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png\" alt=\"\" \/><\/p>\n<\/div>\n<\/article>\n<\/div>\n<div id=\"block-nir-pid4158-websitenoticeblock\" class=\"block--website-notice-block block--website-notice-block--8831 block--content--website-notice-block block--content--website-notice-block--8831 block--4d7a5f5e-26bd-48f8-9ae6-c5112267a7f5 block--4d7a5f5e-26bd-48f8-9ae6-c5112267a7f5--8831 block block-nir-website-notices block-website-notice-block\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PDF Version &nbsp; The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes MENLO PARK, Calif., April 10, 2024 (GLOBE NEWSWIRE) &#8212; Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d), an eyecare technology company [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6,5],"tags":[],"class_list":["post-2313","post","type-post","status-publish","format-standard","hentry","category-news","category-omni"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma - United States<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma\" \/>\n<meta property=\"og:description\" content=\"PDF Version &nbsp; The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes MENLO PARK, Calif., April 10, 2024 (GLOBE NEWSWIRE) &#8212; Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d), an eyecare technology company [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-10T08:01:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-28T10:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png\" \/>\n<meta name=\"author\" content=\"siteadm\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"siteadm\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/\"},\"author\":{\"name\":\"siteadm\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#\\\/schema\\\/person\\\/d505c130ea05814fa602ecd173cb1520\"},\"headline\":\"Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma\",\"datePublished\":\"2024-04-10T08:01:39+00:00\",\"dateModified\":\"2024-05-28T10:03:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/\"},\"wordCount\":1224,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\",\"articleSection\":[\"News\",\"OMNI\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/\",\"url\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/\",\"name\":\"Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma - United States\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\",\"datePublished\":\"2024-04-10T08:01:39+00:00\",\"dateModified\":\"2024-05-28T10:03:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#\\\/schema\\\/person\\\/d505c130ea05814fa602ecd173cb1520\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\",\"contentUrl\":\"https:\\\/\\\/ml.globenewswire.com\\\/media\\\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\\\/tiny\\\/Sight-Sciences-Inc-.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/#\\\/schema\\\/person\\\/d505c130ea05814fa602ecd173cb1520\",\"name\":\"siteadm\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/519e9ee150b29ab28dcb872b4e19cc22b82b10c227d98adc7951385e6335773b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/519e9ee150b29ab28dcb872b4e19cc22b82b10c227d98adc7951385e6335773b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/519e9ee150b29ab28dcb872b4e19cc22b82b10c227d98adc7951385e6335773b?s=96&d=mm&r=g\",\"caption\":\"siteadm\"},\"url\":\"https:\\\/\\\/www.sightsciences.com\\\/us\\\/author\\\/siteadm\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma - United States","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/","og_locale":"en_US","og_type":"article","og_title":"Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma","og_description":"PDF Version &nbsp; The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes MENLO PARK, Calif., April 10, 2024 (GLOBE NEWSWIRE) &#8212; Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d), an eyecare technology company [&hellip;]","og_url":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/","og_site_name":"United States","article_published_time":"2024-04-10T08:01:39+00:00","article_modified_time":"2024-05-28T10:03:41+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","type":"","width":"","height":""}],"author":"siteadm","twitter_card":"summary_large_image","twitter_misc":{"Written by":"siteadm","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/#article","isPartOf":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/"},"author":{"name":"siteadm","@id":"https:\/\/www.sightsciences.com\/us\/#\/schema\/person\/d505c130ea05814fa602ecd173cb1520"},"headline":"Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma","datePublished":"2024-04-10T08:01:39+00:00","dateModified":"2024-05-28T10:03:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/"},"wordCount":1224,"commentCount":0,"image":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/#primaryimage"},"thumbnailUrl":"https:\/\/ml.globenewswire.com\/media\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","articleSection":["News","OMNI"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/","url":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/","name":"Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma - United States","isPartOf":{"@id":"https:\/\/www.sightsciences.com\/us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/#primaryimage"},"image":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/#primaryimage"},"thumbnailUrl":"https:\/\/ml.globenewswire.com\/media\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","datePublished":"2024-04-10T08:01:39+00:00","dateModified":"2024-05-28T10:03:41+00:00","author":{"@id":"https:\/\/www.sightsciences.com\/us\/#\/schema\/person\/d505c130ea05814fa602ecd173cb1520"},"breadcrumb":{"@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/#primaryimage","url":"https:\/\/ml.globenewswire.com\/media\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png","contentUrl":"https:\/\/ml.globenewswire.com\/media\/OGMwNGQxNjktOWY5OC00MzNiLWI1OTItYTdkN2UwYjM2YjBiLTEyMjEzMjQ=\/tiny\/Sight-Sciences-Inc-.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-the-publication-of-large-scale-real-world-migs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sightsciences.com\/us\/"},{"@type":"ListItem","position":2,"name":"Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI\u00ae Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma"}]},{"@type":"WebSite","@id":"https:\/\/www.sightsciences.com\/us\/#website","url":"https:\/\/www.sightsciences.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sightsciences.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.sightsciences.com\/us\/#\/schema\/person\/d505c130ea05814fa602ecd173cb1520","name":"siteadm","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/519e9ee150b29ab28dcb872b4e19cc22b82b10c227d98adc7951385e6335773b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/519e9ee150b29ab28dcb872b4e19cc22b82b10c227d98adc7951385e6335773b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/519e9ee150b29ab28dcb872b4e19cc22b82b10c227d98adc7951385e6335773b?s=96&d=mm&r=g","caption":"siteadm"},"url":"https:\/\/www.sightsciences.com\/us\/author\/siteadm\/"}]}},"_links":{"self":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/posts\/2313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/comments?post=2313"}],"version-history":[{"count":0,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/posts\/2313\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/media?parent=2313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/categories?post=2313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sightsciences.com\/us\/wp-json\/wp\/v2\/tags?post=2313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}